NeuroSense Therapeutics Ltd.
NASDAQ · us_market
No AI insight generated yet for this ticker.
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 44.4K | $33.56K | 0.00% | Trimmed-13.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2025-04-07 | -0.15 | -0.06 | +60.00% |
| 2024-12-18 | -0.11 | -0.11 | — |
| 2024-09-30 | -0.18 | -0.02 | +88.89% |
| 2024-06-24 | -0.20 | -0.35 | -70.73% |
| 2024-04-05 | -0.20 | -0.16 | +20.00% |
| 2023-11-28 | -0.26 | 0.10 | +138.46% |
| 2023-08-16 | -0.28 | -0.44 | -57.14% |
| 2023-06-01 | -0.29 | -0.33 | -13.79% |
| 2023-03-22 | -0.28 | -0.27 | +3.57% |
| 2022-12-01 | -0.28 | -0.25 | +10.71% |
| 2022-11-30 | -0.21 | -0.15 | +28.57% |
| 2022-08-31 | -0.28 | -0.31 | -10.71% |
| 2022-05-31 | -0.18 | -0.24 | -33.33% |
| 2022-04-14 | -0.16 | -0.07 | +56.25% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NRSN | -8.47% | -3.41% | +6.76% | -46.69% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | -11.44% | +1.23% | +10.21% | -59.38% |